Meissner et al. observed a decrease in P-gp expression in patients with dilated cardiomyopathy, based on their study of 15 human cardiac samples.4 Moreover, pharmaceuticals can either inhibit or induce P-gp activity, leading to potential drug-drug interactions, overdoses, and adverse effects. The gene discussed is PGP; the disease is dilated cardiomyopathy.